Prevalence of bleeding events in real-world Japanese registry for Percutaneous Ventricular Assist Device
Journal of Artificial Organs - 2024
Tóm tắt
Bleeding complication is a critical risk factor for outcomes of acute heart failure patients requiring mechanical circulatory support (MCS), including percutaneous catheter-type heart pumps (Impella). The Japanese registry for Percutaneous Ventricular Assist Device (J-PVAD) is an ongoing, large-scale, real-world registry to characterize Japanese patients requiring Impella. Here we analyzed bleeding complication profiles in patients who received Impella. All consecutive Japanese patients who received Impella from October 2017 to January 2020 were enrolled. The 30-day survival and bleeding complications were analyzed. A total of 1344 patients were included: 653 patients received Impella alone, 685 patients received a combination of veno-arterial extracorporeal membrane oxygenation and Impella (ECPELLA), and 6 patients had failed Impella delivery. Overall 30-day survival was 67.0%, with Impella alone at 81.9% and ECPELLA at 52.7%. Overall bleeding/hematoma adverse events with a relation or not-excluded relation to Impella was 6.92%. Among them, the rates of hematoma and bleeding from medical device access sites were 1.41% and 4.09%, respectively. There was no difference between etiologies for these events. This study represents the first 3-year survival and the safety profile focused on bleeding adverse events from the J-PVAD registry. The results show that the real-world frequency of bleeding adverse events for patients who received Impella was an expected range from previous reports, and future real-world studies should aim to expand this data set to improve outcomes and adverse events.
Từ khóa
Tài liệu tham khảo
Besser MW. Post-operative of bleeding, haemolysis and coagulation in mechanical circulatory support patients. Ann Transl Med [Internet]. 2020 [cited 2022 Oct 26];8:832. Available from: /pmc/articles/PMC7396228/
Kapur NK, Whitehead EH, Thayer KL, Pahuja M. The science of safety: complications associated with the use of mechanical circulatory support in cardiogenic shock and best practices to maximize safety. F1000Res [Internet]. 2020 [cited 2022 Oct 26];9:794. Available from: https://f1000research.com/articles/9-794/v1
Lemor A, Dabbagh MF, Cohen D, Villablanca P, Tehrani B, Alaswad K, et al. Rates and impact of vascular complications in mechanical circulatory support. Catheter Cardiovasc Interv [Internet]. 2022 [cited 2022 Oct 26];99:1702–11. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/ccd.30150
Petricevic M, Milicic D, Boban M, Mihaljevic MZ, Baricevic Z, Kolic K, et al. Bleeding and thrombotic events in patients undergoing mechanical circulatory support: a review of literature. Thorac Cardiovasc Surg [Internet]. 2015 [cited 2022 Oct 26];63:636–46. Available from: http://www.thieme-connect.com/products/ejournals/html/10.1055/s-0035-1546296
Succar L, Sulaica EM, Donahue KR, Wanat MA. Management of anticoagulation with Impella® percutaneous ventricular assist devices and review of new literature. J Thromb Thrombolysis [Internet]. 2019 [cited 2022 Oct 26];48:284–91. Available from: https://link.springer.com/article/10.1007/s11239-019-01837-6
Ahmad S, Ahsan MJ, Ikram S, Lateef N, Khan BA, Tabassum S, et al. Impella versus Extracorporeal Membranous Oxygenation (ECMO) for cardiogenic shock: a systematic review and meta-analysis. Curr Probl Cardiol. 2023;48:101427.
Meani P, Lorusso R, Pappalardo F. ECPella: concept, physiology and clinical applications. J Cardiothorac Vasc Anesth. 2022;36:557–66.
Toda K, Ako J, Hirayama A, Kinugawa K, Kobayashi Y, Ono M, et al. Three-year experience of catheter-based micro-axial left ventricular assist device, Impella, in Japanese patients: the first interim analysis of Japan registry for percutaneous ventricular assist device (J-PVAD). J Artif Organs [Internet]. 2022 [cited 2022 Aug 10]. Available from: https://pubmed.ncbi.nlm.nih.gov/35467195/
Ikeda Y, Ako J, Toda K, Hirayama A, Kinugawa K, Kobayashi Y, et al. Short-term outcomes of Impella support in Japanese patients with cardiogenic shock due to acute myocardial infarction – Japanese registry for percutaneous ventricular assist device (J-PVAD). Circ J. 2023;87:588–97.
Nakamura M, Imamura T, Hori M, Yokoyama S, Doi T, Fukahara K, et al. Prognostic implication of risk scoring systems in patients with cardiogenic shock supported by ECMO and Impella. J Artif Organs [Internet]. 2021 [cited 2023 Oct 3];24:372–6. Available from: https://link.springer.com/article/10.1007/s10047-020-01232-6
Nakamura M, Imamura T, Ueno H, Hori M, Ushijima R, Kinugawa K. Impact of the whole activated clotting time during Impella support on short-term prognosis. J Artif Organs [Internet]. 2022 [cited 2023 Oct 3];25:9–15. Available from: https://pubmed.ncbi.nlm.nih.gov/33987744/
Iannaccone M, Venuti G, di Simone E, De Filippo O, Bertaina M, Colangelo S, et al. Comparison of ECMO vs ECpella in patients with non-post-pericardiotomy cardiogenic shock: an updated meta-analysis. Cardiovasc Revasc Med. 2022;40:134–41.
Patel SM, Lipinski J, Al-Kindi SG, Patel T, Saric P, Li J, et al. Simultaneous venoarterial extracorporeal membrane oxygenation and percutaneous left ventricular decompression therapy with impella is associated with improved outcomes in refractory cardiogenic shock. ASAIO J [Internet]. 2019 [cited 2022 Nov 10];65:21–8. Available from: https://journals.lww.com/asaiojournal/Fulltext/2019/01000/Simultaneous_Venoarterial_Extracorporeal_Membrane.3.aspx
Pappalardo F, Schulte C, Pieri M, Schrage B, Contri R, Soeffker G, et al. Concomitant implantation of Impella® on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail [Internet]. 2017 [cited 2022 Nov 10];19:404–12. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.668
Belohlavek J, Hunziker P, Donker DW. Left ventricular unloading and the role of ECpella. Eur Heart J Suppl [Internet]. 2021 [cited 2022 Nov 10];23:A27–34. Available from: https://academic.oup.com/eurheartjsupp/article/23/Supplement_A/A27/6199261
Kalbhenn J, Schmidt R, Nakamura L, Schelling J, Rosenfelder S, Zieger B. Early diagnosis of acquired von Willebrand Syndrome (AVWS) is elementary for clinical practice in patients treated with ECMO therapy. J Atheroscler Thromb [Internet]. 2015 [cited 2023 Oct 4]. Available from: https://www.jstage.jst.go.jp/article/jat/22/3/22_27268/_article/-char/ja/
Tauber H, Ott H, Streif W, Weigel G, Loacker L, Fritz J, Heinz A, Velik-Salchner C. Extracorporeal membrane oxygenation induces short-term loss of high-molecular-weight von Willebrand factor multimers. Anesth Analg [Internet]. 2015 [cited 2023 Oct 4]. Available from: https://journals.lww.com/anesthesia-analgesia/FullText/2015/04000/Extracorporeal_Membrane_Oxygenation_Induces.11.aspx
Vetrovec GW, Kaki A, Dahle TG. A review of bleeding risk with Impella-supported high-risk percutaneous coronary intervention. Heart Int. 2020;14:92.
Nakamura M, Imamura T, Ueno H, Kinugawa K. Current indication and practical management of percutaneous left ventricular assist device support therapy in Japan. J Cardiol. 2020;75:228–32.
Iida M, Shimokawa T. Impella®, percutaneous left ventricular assist device for cardiogenic shock our experiences. J Coron Artery Dis. 2021;27:1–6.
Smith AA, Gupta N. Subclavian Artery Trauma. StatPearls [Internet]. 2022 [cited 2023 Feb 7]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554471/
Kim JH, Brophy DF, Shah KB. Continuous-flow left ventricular assist device–related gastrointestinal bleeding. Cardiol Clin [Internet]. 2018 [cited 2023 Feb 7];36:519–29. Available from: http://www.cardiology.theclinics.com/article/S073386511830849X/fulltext
Thakkar S, Patel HP, Kumar A, Tan BE-X, Arora S, Patel S, et al. Outcomes of Impella compared with intra-aortic balloon pump in ST-elevation myocardial infarction complicated by cardiogenic shock. Am Heart J Plus Cardiol Res Pract. 2021;12:100067.